AbCellera Biologics Inc vs Freeport-McMoRan Inc — how do they compare? AbCellera Biologics Inc trades at $10.92 (market cap $3.17B), while Freeport-McMoRan Inc trades at $66.89 (market cap $96.91B). The key difference: Freeport-McMoRan Inc is far larger — about 30.6× AbCellera Biologics Inc's market cap, and Freeport-McMoRan Inc pays a 0.87% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | FCX | |
|---|---|---|
Market Cap | $3.17B | $96.91B |
Sector | Health | Basic Materials |
52-Week High | $10.36 | $71.73 |
52-Week Low | $2.78 | $35.34 |
Enterprise Value | $2.77B | $103.19B |
Dividend Yield | — | 0.87% |
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) has surged 12.4% to $10.97, driven by positive Phase 2 clinical trial results for its menopause treatment ABCL635. The stock shows strong technical momentum with bullish moving averages, though RSI indicates overbought conditions. Fundamentally, the company remains unprofitable with negative margins but has beaten earnings expectations in recent quarters. Analyst sentiment is overwhelmingly positive with 91.7% buy ratings and a $15.50 consensus price target.
The outlook remains speculative given ABCL's clinical-stage status and persistent losses, but recent drug development success provides significant upside potential. Key risks include clinical trial failures, cash burn concerns, and competitive pressures. The $200 million oversubscribed offering strengthens the balance sheet for continued R&D, positioning the company for potential long-term growth if pipeline assets succeed.
FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.
The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.
Trailing returns across standard periods
Latest headlines on both assets
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →